Search
vTv Therapeutics Inc
VTVTAdd to Watchlist
35.400USD
+0.350+1.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
139.44MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.00%
5 Days
-3.86%
1 Month
+7.27%
6 Months
-10.61%
Year to Date
-11.48%
1 Year
+135.06%
Key Figures
34.790Open
36.690High
61.04KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.55%Turnover Ratio
35.050Prev. Close
34.710Low
1.09MTurnover
LossP/E Static
2.16P/B
0.00%Div Yield TTM
-1.11%ROA
44.00052wk High
1.41Volume Ratio
-18.46MNet Profit
3.94MShares
-0.4838EPS TTM
0.27Beta
4.60%ROE
14.00052wk Low
5.65%Amplitude
100.00%Gross Margin
139.44MMarket Cap
1.31Reward/Risk
4.88%Risk Rate
TradingKey Stock Score of vTv Therapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
vTv Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 59 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 54.80.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
vTv Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
vTv Therapeutics Inc Highlights
StrengthsRisks
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -73.17, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 1.41M shares, increasing 11.70% quarter-over-quarter.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
54.800
Target Price
+51.09%
Upside Space
vTv Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
vTv Therapeutics Inc Info
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
Ticker SymbolVTVT
CompanyvTv Therapeutics Inc
CEOSekhri (Paul Jai)
Websitehttps://vtvtherapeutics.com/
Related Instruments
+1.62%
+3.50%
+3.96%
+3.72%
+3.31%
+6.14%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52818.200
-24.300 (-0.05%)
29614.300
+302.900 (+1.03%)
7498.100
+26.600 (+0.36%)
14950.000
+147.000 (+0.99%)
69496.000
+1348.000 (+1.98%)
6370.300
+17.500 (+0.28%)
68.583
+0.239 (+0.35%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4179.880
+57.970 (+1.41%)
FAQs
What is the current price of vTv Therapeutics Inc (VTVT)?
The current price of vTv Therapeutics Inc (VTVT) is 35.40.
What is the symbol of vTv Therapeutics Inc?
The ticker symbol of vTv Therapeutics Inc is VTVT.
What is the 52-week high of vTv Therapeutics Inc?
The 52-week high of vTv Therapeutics Inc is 44.00.
What is the 52-week low of vTv Therapeutics Inc?
The 52-week low of vTv Therapeutics Inc is 14.00.
What is the market capitalization of vTv Therapeutics Inc?
The market capitalization of vTv Therapeutics Inc is 139.43M.
Is vTv Therapeutics Inc (VTVT) currently rated as Buy, Hold, or Sell?
According to analysts, vTv Therapeutics Inc (VTVT) has an overall rating of Buy, with a price target of 54.80.
What is the Earnings Per Share (EPS TTM) of vTv Therapeutics Inc (VTVT)?
The Earnings Per Share (EPS TTM) of vTv Therapeutics Inc (VTVT) is -3.20.